Angiogenesis Markers in Breast Cancer - Potentially Useful Tools for Priority Setting of Anti-Angiogenic Agents |
Keyhani, Elahe
(Genetics Research Center, University of Social Welfare and Rehabilitation Sciences)
Muhammadnejad, Ahad (Cancer Models Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences) Behjati, Farkhondeh (Genetics Research Center, University of Social Welfare and Rehabilitation Sciences) Sirati, Fereidoon (Mehrad General Hospital) Khodadadi, Faranak (Mehrad General Hospital) Karimlou, Masoud (Biostatistics Department, University of Social Welfare and Rehabilitation Sciences) Moghaddam, Fatemeh A. (Genetics Research Center, University of Social Welfare and Rehabilitation Sciences) Pazhoomand, Reza (Genetics Research Center, University of Social Welfare and Rehabilitation Sciences) |
1 | Story HL, Love RR, Salim R, et al (2012). Ginsburg OMImproving outcomes from breast cancer in a low-income country: lessons from bangladesh. Int J Breast Cancer, 2012, 423562 |
2 | Taghavi A, Fazeli Z, Vahedi M, et al (2012). Increased trend of breast cancer mortality in Iran. Asian Pac J Cancer Prev, 13, 367-70 과학기술학회마을 DOI ScienceOn |
3 | Teodoro Jose G (2008). The p53 Tumor-suppressor geneinhibiting tumor angiogenesis. US Oncological Review, 4, 15-8. |
4 | The Breast Health Global Initiative (2013). http://portal.bhgi.org/Pages/Default.aspx. Accesses October 2013 |
5 | Wen XF, Yang G, Mao W, et al (2006). HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene, 25, 6986-96 DOI ScienceOn |
6 | World Bank (2010). Gross domestic product World Development Indicators database. http://www.worldbank.org/ |
7 | Xu BH, Jiang ZF, Shen ZZ, et al (2012). Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study. Chin Med J (Engl), 125, 764 9 |
8 | Yip CH, Smith RA, Anderson BO, et al (2008). Breast Health Global Initiative Early Detection Panel, Guideline implementation for breast healthcare in low- and middle income countries: early detection resource allocation. Cancer, 113, 2244-56 DOI ScienceOn |
9 | Hammond ME, Hayes DF, Dowsett M, et al (2010). American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Pathologists' Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Breast Care (Basel), 5, 185-7 DOI ScienceOn |
10 | Kadivar M, Mafi N, Joulaee A, Shamshiri A, Hosseini N (2012). Breast cancer molecular subtypes and associations with clinicopathological characteristics in Iranian women, 2002-2011. Asian Pac J Cancer Prev, 13, 1881-6 과학기술학회마을 DOI ScienceOn |
11 | Kerbel RS (2008). Tumor angiogenesis. N Engl J Med, 8, 358, 2039-49 DOI ScienceOn |
12 | Kobayashi T, Iwaya K, Moriya T, et al (2013). A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer. BMC Clin Pathol, 6, 13-5 |
13 | Kumar R, Yarmand-Bagheri R (2001). The role of HER2 in angiogenesis. Semin Oncol, 28, 27-32. DOI |
14 | Lawrence N Shulman, Walter Willett, Amy Sievers, Felicia M Knaul (2010). Breast Cancer in Developing Countries: Opportunities for Improved Survival. J Oncol, 2010, 595167. |
15 | Le Bourhis X, Romon R, Hondermarck H (2010). Role of endothelial progenitor cells in breast cancer angiogenesis: from fundamental research to clinical ramifications. Breast Cancer Res Treat, 120, 17-24 DOI ScienceOn |
16 | Lee JB, Woo OH, Park KH, et al (2011). Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials. Invest New Drugs, 29, 182-8 DOI ScienceOn |
17 | Mousavi SM, Gouya MM, Ramazani R, et al (2009). Cancer incidence and mortality in Iran. Ann Oncol, 20, 556-63 |
18 | Lenzer J (2011). FDA committee votes to withdraw bevacizumab for breast cancer. BMJ, 5, 343, 4244 DOI |
19 | Mackey JR, Kerbel RS, Gelmon KA, et al (2012). Controlling angiogenesis in breast cancer: a systematic review of antiangiogenic trials. Cancer Treat Rev, 38, 673-88 DOI ScienceOn |
20 | Mokarian F, Ramezani MA, Heydari K, Tabatabaeian M, Tavazohi H (2011). Epidemiology and trend of cancer in Isfahan. J Res Med Sci, 16, 1228-33 |
21 | Mousavi SM, Mohaghegghi MA, Mousavi-Jerrahi A, Nahvijou A, Seddighi Z (2006). Burden of breast cancer in Iran: a study of the Tehran population based cancer registry. Asian Pac J Cancer Prev, 7, 571-4 |
22 | Pedraza AM, Pollan M, Pastor-Barriuso R, Cabanes A (2012). Disparities in breast cancer mortality trends in a middle income country. Breast Cancer Res Treat, 134, 1199-207 DOI |
23 | Refaat T, Choi M, Gaber G, et al (2013). Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer. Am J Clin Oncol. [Epub ahead of print] |
24 | Altekruse SF, Kosary CL, Krapcho M, et al (2010). SEER Cancer Statistics Review, 1975 2007. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2007/ |
25 | Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz, et al (2007); Testing in Breast Cancer. J Clinical Oncol, 25, 118-45 |
26 | Albanell J, Codony J, Rovira A, Mellado B, Gascon P (2003). Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol, 532, 253-68 DOI |
27 | Biesaga B, Niemiec J, Ziobro M (2012). Microvessel density and status of p53 protein as potential prognostic factors for adjuvant anthracycline chemotherapy in retrospective analysis of early breast cancer patients group. Pathol Oncol Res, 18, 949-60 DOI ScienceOn |
28 | Al-Foheidi M, Al-Mansour MM, Ibrahim EM (2013). Breast cancer screening: review of benefits and harms, and recommendations for developing and low-income countries. Med Oncol, 30, 471 DOI ScienceOn |
29 | Anusheel Munshi, Sudeep Gupta, Benjamin Anderson, et al (2012). Guidelines for locoregional therapy in primary breast cancer in developing countries: The results of an expert panel at the 8th Annual Women's Cancer Initiative-Tata Memorial Hospital (WCI-TMH) Conference. Indian J Med Paediatr Oncol, 33, 112-22 DOI ScienceOn |
30 | Arnes JB, Stefansson IM, Straume O, et al (2011). Vascular proliferation is a prognostic factor in breast cancer. Breast Cancer Res Treat, 133, 501-10 |
31 | Calza S, Hall P, Auer G, et al (2006). Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res, 8, 34 |
32 | Davari M, Yazdanpanah F, Aslani A, et al (2013). The Direct Medical Costs of Breast Cancer in Iran: Analyzing the Patient's Level Data from a Cancer Specific Hospital in Isfahan. Int J Prev Med, 4, 748-54 |
33 | Dhakal HP, Bassaova A, Naume B, et al (2009). Breast carcinoma vascularity: a comparison of manual micrivessel count and Chalkley count. Histol Histopathol, 34, 1049-59 |
34 | El Saghir NS, Adebamowo CA, Anderson BO, et al (2011). Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative. Breast, 2, 3-11 |
35 | Singh SR (2012). Stem cell niche in tissue homeostasis, aging and cancer. Curr Med Chem, 19, 5965-74 DOI |
36 | Folkman J (2002). Role of angiogenesis in tumor growth and metastasis. Semin Oncol, 29, 15-8 DOI |
37 | Gligorov J, Arsovski O, Belkacemi Y, et al (2011). Guidelines, minimal requirements and standard of cancer care around the Mediterranean Area: report from the Collaborative AROME (Association of Radiotherapy and Oncology of the Mediterranean Area) working parties. Crit Rev Oncol Hematol, 78, 1-16 DOI ScienceOn |
38 | Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 22, 1736-47 DOI ScienceOn |
39 | Rouhollahi MR, Mohammad Nejad S, Harirchi I, et al (2013). Policy Brief Management of Herceptin (Trastuzumab) in Patients with Breast Cancer in Iran: Procurement, Allocation, Patient Eligibility Criteria, Prescription and Financial Protection. Hakim, 15, 270-80 |
40 | Silva H, Conboy IM (2008). Aging and stem cell renewal. StemBook [Internet]. Cambridge (MA): Harvard Stem Cell Institute, 2008 Jul 15 |
41 | Sopel M, Kasprzyk I, Berdowska I (2005). Maspin and c-erbB-2 expression in correlation with microvessel density in invasive ductal breast cancer. Folia Histochem Cytobiol, 43, 109-16 |
42 | Steven S. Coughlin, Donatus U. Ekwueme (2009). Breast cancer as a global health concern. Cancer Epidemiol, 33, 315-8 DOI ScienceOn |